PEOPLE - Cypress Bioscience (US) makes appointment:
This article was originally published in Clinica
Executive Summary
Martin Keller has joined the board of Cypress Bioscience (San Diego, California), a company that develops agents for the diagnosis and treatment of rheumatologic and blood platelet disorders. A psychiatric illness specialist, Dr Keller is currently chairman of the department of psychiatry and human behaviour at the Brown University School of Medicine, in Providence, Rhode Island. At Cypress, he will additionally join the newly formed psychopharmacology advisory board, focusing on developing tests and therapies for fibromyalgia syndrome.
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.